Corticosteroid Exposure in Older Adults Did Not Erode Reported Quality of Life
Long-term corticosteroid therapy in adults aged 65 years and older with giant cell arteritis or polymyalgia rheumatica did not track with a measurable decline in self-reported quality of life in this Spanish cohort. The study is clinically relevant because both diseases are common in later life and often require prolonged glucocorticoid exposure, a treatment strategy that can improve inflammatory symptoms while raising concern for metabolic and vascular harm.
Fifty patients receiving corticosteroids for more than six months were assessed at the main hospital in Zaragoza, Spain, between February and June 2025. Investigators paired treatment history with patient-reported outcomes, using the validated SF-36 to measure quality of life and the PREDIMED questionnaire to gauge adherence to the Mediterranean diet. The clinical question was straightforward: whether greater steroid burden translated into worse daily function, worse digestive tolerance, or a broader deterioration in well-being.
The answer was restrained rather than dramatic. Neither current glucocorticoid dose nor cumulative exposure showed significant associations with any of the evaluated quality-of-life domains. Correlation coefficients ranged from -0.172 to 0.199, and p values ranged from 0.167 to 0.966. Those numbers do not support a dose-dependent deterioration in the patient-reported experience captured by SF-36, at least in this small cross-sectional sample.
Blood Pressure Emerged as the Clearest Treatment-Linked Harm
One signal stood out sharply. Corticosteroid treatment was associated with an increased risk of high blood pressure (p = 0.038).
This finding fits the known physiology of glucocorticoids. By promoting sodium retention, fluid expansion, and vascular sensitivity to pressor stimuli, corticosteroids can push blood pressure upward even when other symptoms remain controlled. In older adults already vulnerable to arterial stiffness and multimorbidity, that effect can appear quietly before it becomes clinically obvious at the bedside. The absence of a broad quality-of-life penalty does not blunt the need to monitor blood pressure carefully; it simply means the burden may be concentrated in a cardiovascular domain rather than a global decline in how patients rate their lives.
Digestive outcomes moved in the opposite direction. Corticosteroid treatment was associated with the absence of worsening gastrointestinal symptoms (p = 0.035). The phrasing matters clinically: the cohort did not show progressive digestive deterioration with prolonged exposure, and that may reflect the practical realities of glucocorticoid prescribing in inflammatory rheumatic disease, where symptom control can reduce systemic inflammatory discomfort and improve overall tolerability. Still, this should not be read as proof that steroids protect the gut. The result is narrower than that, limited to the outcomes captured here.
Longer Treatment Duration Was Linked to Better Perceived Mental Health
A second unexpected signal surfaced in the mental health domain. Longer corticosteroid treatment was associated with better perceived mental health (p = 0.036). In a population living with painful, disabling vasculitic and rheumatologic disease, symptom relief may translate into less distress, better sleep, and improved day-to-day confidence. Glucocorticoids can rapidly suppress the inflammatory burden that drives headache, stiffness, fatigue, and proximal pain, and the psychological payoff of that control may show up in patient-reported mental health before it is reflected in any laboratory marker.
The result is not a license to view corticosteroids as psychologically beneficial in the abstract. Steroids can provoke mood changes, insomnia, and agitation in some patients. In this cohort, however, the longer treatment duration aligned with better perceived mental health rather than worse scores, suggesting that disease suppression may have outweighed treatment-related psychological strain for many participants. Cross-sectional data cannot establish directionality, and the association may reflect the experience of patients whose disease was sufficiently controlled to feel better overall.
Diet Adherence Did Not Change the Quality-of-Life Signal
Adherence to the Mediterranean diet, measured with the PREDIMED questionnaire, was not associated with improved quality-of-life outcomes. All comparisons were nonsignificant. In practical terms, dietary adherence did not separate better and worse SF-36 profiles in this sample, nor did it alter the treatment-QoL relationship in a measurable way.
That should not be mistaken for evidence that nutrition is irrelevant in older adults with inflammatory disease. It means only that within this cohort, diet adherence did not correlate with the reported QoL endpoints. The small sample size and the cross-sectional design limit the ability to detect subtler interactions between diet, symptom burden, steroid exposure, and comorbid disease. Patients with GCA and PMR often carry competing drivers of fatigue, pain, and cardiovascular risk, and those factors can easily overwhelm a single dietary variable in a modest cohort.
What This Means at the Bedside
For clinicians treating giant cell arteritis and polymyalgia rheumatica in older adults, the study supports a balanced reading of prolonged corticosteroid use. The therapy did not appear to worsen overall patient-reported quality of life or digestive health in this cohort, but it did associate with hypertension, a complication that can silently accumulate while symptoms feel controlled. Blood pressure surveillance remains essential, especially in patients already at risk for vascular disease, stroke, or chronic kidney stress.
The data also suggest that patient experience cannot be reduced to steroid dose alone. Inflammatory disease control may preserve or even improve some aspects of perceived well-being, including mental health, even as cardiovascular risk rises. That duality is common in long-term rheumatologic care: a medication can be simultaneously effective and harmful, with the balance depending on the outcome being measured.
The study’s cross-sectional design leaves several questions open. The sample was small, drawn from a single hospital, and limited to patients already receiving corticosteroids for more than six months. No causal inference is possible, and the design cannot show whether better mental health followed symptom control or whether patients who felt better were simply more likely to remain engaged in treatment. Even so, the data provide a useful reminder that in older adults with GCA and PMR, prolonged corticosteroid exposure may not necessarily erase quality of life, but it does demand careful cardiovascular monitoring and ongoing reassessment of risk against symptom control.